ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do Proactive…
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do Proactive…
Roche to present new data at ASCO 2026, reinforcing giredestrant’s potential to transform the treatment paradigm in early breast cancer
F. Hoffmann-La Roche Ltd New giredestrant data from the lidERA study on its potential as a new standard…
Roche to present new data at ASCO 2026, reinforcing giredestrant’s potential to transform the treatment paradigm in early breast cancer
F. Hoffmann-La Roche Ltd New giredestrant data from the lidERA study on its potential as a new standard…
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Pluvicto®PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali®…
Roche Breast Cancer Data At ASCO 2026 Tests Pipeline Narrative
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Roche to present new data at ASCO 2026, reinforcing giredestrant’s potential to transform the treatment paradigm in early breast cancer
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant…
AstraZeneca, Genentech, Roche, Takeda Day 3 news
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…